HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Astra's Foscavir approved for acyclovir-resistant herpes infections in immunocompromised patients.

  • News

Executive Summary

ASTRA USA FOSCAVIR APPROVAL FOR TREATMENT OF ACYCLOVIR-RESISTANT HSV indication makes the antiviral drug the first approved therapy for acyclovir-resistant herpes simplex virus infections in immunocompromised patients. Foscavir (foscarnet sodium) has been on the market since September 1991 as a treatment for AIDS-related cytomegalovirus retinitis. Glaxo Wellcome's Zovirax (acyclovir) is the first-line treatment for HSV.

Table

View full table

Tags:
Latest Headlines

Beiersdorf Partners With Biopharma For Anti-Aging Skin Care Innovation; Beauty Business News

Clasado, Probi Funded Study Shows Synergistic Effect Of Synbiotic Combination

Qunol Acquisition Gets Sanofi CHC Off To Flying Start

Walmart Lays Out Expectations For Beauty Brands' MoCRA Compliance

See All
UsernamePublicRestriction

Register

PS026471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By